Chemo plus targeted radiation versus chemo alone for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (not lymphoma) confirmed by pathology (biopsy/surgery results).
- Your liver tumors can be treated fully with the radiation plan, and each tumor setup fits the study size limits (no tumor over 25 cm).
- You have 5 or fewer measurable liver lesions, checked on a contrast CT or MRI within the last 90 days.
- Your cancer can’t be removed by surgery (it’s considered medically or surgically unresectable).
- You can have standard blood counts and liver lab results (for example, platelets, bilirubin, and INR must be in acceptable ranges).
- You’re 18 or older, can give consent, and have a life expectancy of more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This study compares two ways of delivering targeted radiation to treat hepatocellular carcinoma (liver cancer): radioembolization, which uses tiny beads to deliver radiation directly through blood vessels, and external beam radiation therapy, which aims radiation from outside the body. The trial will help doctors understand which approach works better for patients with a limited number of tumors.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.